Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma

Cimarron E. Sharon, G.N. Tortorello, L. Kevin, A.C. Huang, Xiao‐Ming Xu, L. R. Giles, Suzanne McGettigan, Kristen Kreider, Lynn M. Schuchter, Ashish Jacob Mathew, Ravi K. Amaravadi, Phyllis A. Gimotty, John T. Miura, Giorgos C. Karakousis, Tara C. Mitchell